Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2024-11-03
Based on 391 first isolates · GER · Cystitis (lower UTI) · 2023-11-05 → 2024-11-03
Geriatrics
Per-organism detail: GER urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 86 % (82 %–89 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (6 %), Klebsiella pneumoniae (4 %), Pseudomonas aeruginosa (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
86 %
79 %
n = 28
meropenem MEM
trend · Escherichia coli reserve
83 %
71 %
n = 28
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
79 %
64 %
n = 28
ceftriaxone CRO
trend · Escherichia coli
77 %
68 %
n = 28
ciprofloxacin CIP
trend · Escherichia coli
77 %
68 %
n = 28
mecillinam MEC
trend · Escherichia coli lower UTI only
75 %
64 %
n = 28
74 %
68 %
n = 28
trimethoprim TMP
trend · Escherichia coli lower UTI only
67 %
75 %
n = 28
51 %
64 %
n = 28
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
15 %
29 %
n = 28
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
7 %
n = 28
3 %
0 %
n = 28

Most likely organisms for this profile

Escherichia coli
61 %
Enterococcus faecalis
11 %
Klebsiella pneumoniae
8 %
Proteus mirabilis
6 %
Staphylococcus aureus
4 %
Klebsiella oxytoca
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.